Clinical Trial Update: Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis

View source ↗

Summary

This clinical trial update evaluates the accuracy of NGAL, a renal injury biomarker, in patients with cirrhosis, including those with acute kidney injury and he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatorenal Syndrome
• Kidney Injury

Snippet

Sponsor: University of Sao Paulo | Conditions: Acute Kidney Injury, Hepatorenal Syndrome | Status: UNKNOWN